Malignant pleural effusion

Area of Science:

• Pulmonology
• Oncology
• Thoracic Surgery

Background:

• Malignancy is the leading cause of exudative pleural effusion in individuals over 60.
• Effective management of malignant pleural effusion is crucial for reducing morbidity and enhancing quality of life.

Purpose of the Study:

• To compare the efficacy of bleomycin versus tetracycline in chemical pleurodesis for malignant pleural effusions.

Main Methods:

• A 13-center randomized trial involving 1 g of tetracycline and 60 U of bleomycin.
• Patients with malignant pleural effusion underwent tube thoracostomy followed by chemical pleurodesis.

Main Results:

• Bleomycin demonstrated a longer median time to recurrence (over 46 days) compared to tetracycline (32 days).
• The 30-day recurrence rate was significantly lower for bleomycin (36%) than for tetracycline (67%).
• The 90-day recurrence rate also favored bleomycin (30%) over tetracycline (53%).

Conclusions:

• Intrapleural bleomycin is superior to tetracycline for controlling malignant pleural effusions.
• For patients unresponsive to tube thoracostomy and chemical pleurodesis, consider pleuroperitoneal shunting or pleurectomy.